GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days

  • GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has surged 27% in one month and over 17% on a year-to-date (YTD) basis.

Ankit Gohel
Published18 Feb 2025, 02:21 PM IST
GlaxoSmithKline share price has delivered multibagger returns of more than 110% over the past two years.
GlaxoSmithKline share price has delivered multibagger returns of more than 110% over the past two years.(Photo: Bloomberg)

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to 2,744.95 apiece on the BSE.

The rally in GlaxoSmithKline Pharmaceuticals shares comes after the company reported robust growth in its Q3 results. The biopharma company reported its earnings for the third quarter of FY25 on Friday, February 14.

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results.

GlaxoSmithKline Pharmaceuticals Q3 Results

GlaxoSmithKline Pharmaceuticals reported a 400% jump in consolidated net profit to 230 crore in Q3FY25 as compared to 46 crore in the corresponding quarter last year.

The company’s revenue in the quarter ended December 2024 grew 18% to 949.42 crore from 805.26 crore, year-on-year (YoY).

Also Read | Auto Sector Q3 Results: Growth slows, profits hit; Maruti, M&M top picks

EBITDA in Q3FY25 increased 33.8% to 291.9 crore from 218.1 crore, while EBITDA margin expanded to 30.7% from 27.1%, YoY.

GSK Pharma’s flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains.

The company’s innovative Respiratory portfolio, led by Nucala and Trelegy, achieved robust growth, further expanding patient access across India, GlaxoSmithKline Pharmaceuticals said.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines. The adult vaccines division continues to gain momentum with Shingrix (Herpes Zoster Vaccine – recombinant, adjuvanted), as the company spearheads the expansion of adult immunisation in India, it added.

Also Read | Gillette India shares jump 14% after Q3 results, ahead of dividend record date

GlaxoSmithKline Stock Price Trend

GlaxoSmithKline share price surged 27% in one month and over 17% on a year-to-date (YTD) basis. The stock has fallen 10% in six months, but has risen 16% in one year.

However, over the past two years, GlaxoSmithKline share price has delivered multibagger returns of more than 110%.

At 2:20 PM, GlaxoSmithKline shares were trading 7.92% higher at 2,516.95 apiece on the BSE

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Business NewsMarketsStock MarketsGlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days
MoreLess